[5] Common side effects include blurry vision, redness of the eye, itchiness, and darkening of the iris.

In the United States, latanoprost is indicated for the reduction of elevated intraocular pressure in people with open-angle glaucoma or ocular hypertension.

[11] Meta-analysis suggests that latanoprost is more effective than timolol in lowering intraocular pressure (IOP).

evidence suggests that this pigmentation is benign, careful lifetime evaluation of patients is still justified.

[12] People who had elevated IOP despite iridotomy and/or iridectomy (including people of Asian descent), latanoprost was significantly more effective than timolol in two double-blind, monotherapy trials (8.2 and 8.8 mm Hg vs 5.2 and 5.7 mm Hg for latanoprost vs timolol at 12 and 2 weeks, respectively).

[13] Listed from most to least common:[14][15] Research suggests that wiping the eye with an absorbent pad after the administration of eye drops can result in shorter eyelashes and a lesser chance of hyperpigmentation in the eyelid, compared to not wiping off excess fluid.

Paradoxically, the concomitant use of latanoprost and bimatoprost or other prostaglandins may result in increased intraocular pressure.

[5][3] In September 2023, the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Catiolanze, intended for the reduction of elevated intraocular pressure in adults with open angle glaucoma or ocular hypertension and in children from four years and adolescents with elevated intraocular pressure and pediatric glaucoma.

[3][4] Latanoprost is sold under many brand names including Xalatan,[2][19] Iyuzeh,[20] Xelpros,[21] and Catiolanze.